Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Colburn

Showing results (61-70 of 216) with videos related to

Pageof 22
Sort By:
Molecular Carcinogenesis|January 1, 1992
Differential c-jun expression in response to tumor promoters in JB6 cells sensitive or resistant to neoplastic transformationE T Ben-Ari, L R Bernstein, N H Colburn
The Biochemical Journal|June 1, 1997
Differential functional significance of AP-1 binding sites in the promoter of the gene encoding mouse tissue inhibitor of metalloproteinases-3H Kim, W D Pennie, Y Sun, et al.
Oncogene|June 13, 2003
Pdcd4 suppresses tumor phenotype in JB6 cells by inhibiting AP-1 transactivationHsin-Sheng Yang, Jennifer L Knies, Cristi Stark, et al.
Molecular Cancer Therapeutics|February 27, 2004
Characterization of programmed cell death 4 in multiple human cancers reveals a novel enhancer of drug sensitivityAaron P Jansen, Corinne E Camalier, Cristi Stark, et al.
Carcinogenesis|January 1, 1987
DNA sequences in human nasopharyngeal carcinoma cells that specify susceptibility to tumor promoter-induced neoplastic transformationM I Lerman, A Sakai, K T Yao, et al.
Molecular Carcinogenesis|December 7, 2000
Induced expression of dominant-negative c-jun downregulates NFkappaB and AP-1 target genes and suppresses tumor phenotype in human keratinocytesJ J Li, Y Cao, M R Young, et al.
Experimental Cell Research|February 22, 2002
Activation of NF-kappaB is required for PDGF-B chain to transform NIH3T3 cellsTakeshi Shimamura, Tin-Chen Hsu, Nancy H Colburn, et al.
Carcinogenesis|May 1, 1994
Differential transformation efficiency but not AP-1 induction under anchorage-dependent and -independent conditionsZ Dong, J L Cmarik, E J Wendel, et al.
Molecular Interventions|April 7, 2010
Have tumor suppressor PDCD4 and its counteragent oncogenic miR-21 gone rogue?Matthew R Young, Arti N Santhanam, Noriko Yoshikawa, et al.
The Journal of Nutritional Biochemistry|June 19, 2012
Cancer stem cells: potential target for bioactive food componentsYoung S Kim, William Farrar, Nancy H Colburn, et al.
Pageof 22

Showing results (61-70 of 216) with videos related to

Sort By:
Pageof 22
Molecular Carcinogenesis|January 1, 1992
Differential c-jun expression in response to tumor promoters in JB6 cells sensitive or resistant to neoplastic transformationE T Ben-Ari, L R Bernstein, N H Colburn
The Biochemical Journal|June 1, 1997
Differential functional significance of AP-1 binding sites in the promoter of the gene encoding mouse tissue inhibitor of metalloproteinases-3H Kim, W D Pennie, Y Sun, et al.
Oncogene|June 13, 2003
Pdcd4 suppresses tumor phenotype in JB6 cells by inhibiting AP-1 transactivationHsin-Sheng Yang, Jennifer L Knies, Cristi Stark, et al.
Molecular Cancer Therapeutics|February 27, 2004
Characterization of programmed cell death 4 in multiple human cancers reveals a novel enhancer of drug sensitivityAaron P Jansen, Corinne E Camalier, Cristi Stark, et al.
Carcinogenesis|January 1, 1987
DNA sequences in human nasopharyngeal carcinoma cells that specify susceptibility to tumor promoter-induced neoplastic transformationM I Lerman, A Sakai, K T Yao, et al.
Molecular Carcinogenesis|December 7, 2000
Induced expression of dominant-negative c-jun downregulates NFkappaB and AP-1 target genes and suppresses tumor phenotype in human keratinocytesJ J Li, Y Cao, M R Young, et al.
Experimental Cell Research|February 22, 2002
Activation of NF-kappaB is required for PDGF-B chain to transform NIH3T3 cellsTakeshi Shimamura, Tin-Chen Hsu, Nancy H Colburn, et al.
Carcinogenesis|May 1, 1994
Differential transformation efficiency but not AP-1 induction under anchorage-dependent and -independent conditionsZ Dong, J L Cmarik, E J Wendel, et al.
Molecular Interventions|April 7, 2010
Have tumor suppressor PDCD4 and its counteragent oncogenic miR-21 gone rogue?Matthew R Young, Arti N Santhanam, Noriko Yoshikawa, et al.
The Journal of Nutritional Biochemistry|June 19, 2012
Cancer stem cells: potential target for bioactive food componentsYoung S Kim, William Farrar, Nancy H Colburn, et al.
Pageof 22